Upstream Bio (UPB) Competitors $6.87 +0.06 (+0.88%) Closing price 04:00 PM EasternExtended Trading$6.88 +0.01 (+0.22%) As of 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock UPB vs. CGON, HRMY, ARQT, JANX, TVTX, AGIO, TARS, APGE, VERA, and IRONShould you be buying Upstream Bio stock or one of its competitors? The main competitors of Upstream Bio include CG Oncology (CGON), Harmony Biosciences (HRMY), Arcutis Biotherapeutics (ARQT), Janux Therapeutics (JANX), Travere Therapeutics (TVTX), Agios Pharmaceuticals (AGIO), Tarsus Pharmaceuticals (TARS), Apogee Therapeutics (APGE), Vera Therapeutics (VERA), and Disc Medicine (IRON). These companies are all part of the "pharmaceutical products" industry. Upstream Bio vs. CG Oncology Harmony Biosciences Arcutis Biotherapeutics Janux Therapeutics Travere Therapeutics Agios Pharmaceuticals Tarsus Pharmaceuticals Apogee Therapeutics Vera Therapeutics Disc Medicine CG Oncology (NASDAQ:CGON) and Upstream Bio (NASDAQ:UPB) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, media sentiment, valuation, community ranking, earnings, institutional ownership, analyst recommendations, risk and profitability. Does the media refer more to CGON or UPB? In the previous week, CG Oncology had 12 more articles in the media than Upstream Bio. MarketBeat recorded 14 mentions for CG Oncology and 2 mentions for Upstream Bio. Upstream Bio's average media sentiment score of 1.84 beat CG Oncology's score of 0.80 indicating that Upstream Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CG Oncology 4 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Upstream Bio 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Do analysts recommend CGON or UPB? CG Oncology currently has a consensus price target of $63.88, suggesting a potential upside of 137.10%. Upstream Bio has a consensus price target of $56.50, suggesting a potential upside of 729.66%. Given Upstream Bio's higher possible upside, analysts clearly believe Upstream Bio is more favorable than CG Oncology.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CG Oncology 0 Sell rating(s) 0 Hold rating(s) 9 Buy rating(s) 1 Strong Buy rating(s) 3.10Upstream Bio 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the MarketBeat Community believe in CGON or UPB? CG Oncology received 19 more outperform votes than Upstream Bio when rated by MarketBeat users. However, 100.00% of users gave Upstream Bio an outperform vote while only 92.00% of users gave CG Oncology an outperform vote. CompanyUnderperformOutperformCG OncologyOutperform Votes2392.00% Underperform Votes28.00%Upstream BioOutperform Votes4100.00% Underperform VotesNo Votes Which has stronger earnings and valuation, CGON or UPB? Upstream Bio has higher revenue and earnings than CG Oncology. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCG Oncology$684K2,994.83-$48.61MN/AN/AUpstream Bio$2.37M154.13N/AN/AN/A Do institutionals and insiders believe in CGON or UPB? 26.6% of CG Oncology shares are owned by institutional investors. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Is CGON or UPB more profitable? Upstream Bio has a net margin of 0.00% compared to CG Oncology's net margin of -10,642.98%. Upstream Bio's return on equity of 0.00% beat CG Oncology's return on equity.Company Net Margins Return on Equity Return on Assets CG Oncology-10,642.98% -18.97% -15.36% Upstream Bio N/A N/A N/A SummaryCG Oncology and Upstream Bio tied by winning 7 of the 14 factors compared between the two stocks. Remove Ads Get Upstream Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for UPB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart UPB vs. The Competition Export to ExcelMetricUpstream BioPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$365.30M$6.92B$5.65B$8.06BDividend YieldN/A2.72%4.57%4.01%P/E RatioN/A7.2023.1619.03Price / Sales154.13226.01386.8193.17Price / CashN/A65.6738.1634.64Price / BookN/A6.476.914.33Net IncomeN/A$141.90M$3.20B$247.06M7 Day Performance-10.63%-3.20%-2.30%-0.37%1 Month Performance-14.12%-5.64%2.86%-3.85%1 Year PerformanceN/A-7.47%10.51%1.27% Upstream Bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)UPBUpstream BioN/A$6.87+0.9%$56.50+722.4%N/A$368.51M$2.37M0.0038Positive NewsCGONCG Oncology1.2223 of 5 stars$27.67-0.5%$63.88+130.8%-34.3%$2.10B$684,000.000.0061Earnings ReportAnalyst ForecastNews CoverageHRMYHarmony Biosciences4.4516 of 5 stars$34.32+4.9%$53.11+54.8%-0.5%$1.97B$714.73M16.27200ARQTArcutis Biotherapeutics2.5397 of 5 stars$16.42+12.3%$18.80+14.5%+67.8%$1.95B$196.54M-9.17150Short Interest ↓Positive NewsHigh Trading VolumeJANXJanux Therapeutics2.6302 of 5 stars$31.51+2.7%$92.44+193.4%-21.5%$1.86B$10.59M-26.9330Positive NewsTVTXTravere Therapeutics2.7735 of 5 stars$20.87+5.8%$30.62+46.7%+165.6%$1.85B$233.18M-5.09460News CoveragePositive NewsAGIOAgios Pharmaceuticals4.3476 of 5 stars$31.99+3.4%$56.57+76.8%+5.9%$1.83B$36.50M2.82390Short Interest ↓Positive NewsTARSTarsus Pharmaceuticals2.2392 of 5 stars$47.49-1.2%$63.67+34.1%+46.5%$1.82B$182.95M-12.4650Insider TradePositive NewsAPGEApogee Therapeutics2.408 of 5 stars$40.35+1.0%$92.17+128.4%-42.4%$1.82BN/A-16.6791Positive NewsVERAVera Therapeutics3.1302 of 5 stars$28.07+0.3%$64.67+130.4%-39.5%$1.79BN/A-10.7540Positive NewsIRONDisc Medicine2.9566 of 5 stars$51.27+0.5%$89.10+73.8%-13.3%$1.77BN/A-12.8830Insider Trade Remove Ads Related Companies and Tools Related Companies CGON Alternatives HRMY Alternatives ARQT Alternatives JANX Alternatives TVTX Alternatives AGIO Alternatives TARS Alternatives APGE Alternatives VERA Alternatives IRON Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:UPB) was last updated on 3/28/2025 by MarketBeat.com Staff From Our PartnersElon Warns: Exec Order 14024 Targets DollarExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredDo this Before Elon's Reveal on April 23rdElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredTrump’s Treasure Map [Pic inside]We were shown this map by former Presidential Advisor, Jim Rickards, one of the most politically connected men...Paradigm Press | SponsoredTwo Unmistakable Patterns Return…The signs suggest we're entering one of those rare periods now. That's why Central Banks are buying gold at...Golden Portfolio | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredJust Revealed: The chip company making AI look primitiveIn his just-released video presentation, this renowned market strategist — who's been called "one of the most ...InvestorPlace | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Upstream Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Upstream Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
